How to Use Cagrilintide
Complete guide to Cagrilintide dosing, administration, timing, and protocol recommendations.
Quick Overview
A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).
Dosing Guidelines
Common Dose
2.4 mg weekly
Frequency
Once weekly
Dose Range
1.0-2.4 mg weekly (dose escalation)
Note: Most effective when combined with semaglutide (CagriSema). Works through amylin pathway which is complementary to GLP-1 mechanism. Dose escalation typically used to minimize GI side effects. Not yet commercially available - still in clinical trials.
Administration Method
Subcutaneous injection once weekly
Best Time to Take
Any consistent time weekly
Once-weekly injection provides sustained amylin receptor activation. Timing is flexible but should be consistent week to week.
Protocol Duration
Long-term / chronic use expected
Possible Side Effects
Not everyone experiences these. Individual responses vary.
- •Nausea (common, usually transient)
- •Vomiting
- •Diarrhea
- •Constipation
- •Abdominal pain
Frequently Asked Questions
What is the recommended dose for Cagrilintide?
2.4 mg weekly
How do you administer Cagrilintide?
Subcutaneous injection once weekly
When is the best time to take Cagrilintide?
Any consistent time weekly
How long should you use Cagrilintide?
Long-term / chronic use expected
This information is for educational purposes only. Always consult with a healthcare professional before using any peptide. Dosing information is based on research literature and community reports, not medical advice.